[show abstract][hide abstract] ABSTRACT: Inflammatory bowel disease (IBD) is a chronic and recurring inflammation of the gastroin-testinal tract; however, current pharmaceutical treatments are only moderately effective and have potential long-term toxicity, therefore novel IBD therapies are required. Hen egg white has been shown to be an abundant source of novel immunomodulating proteins and peptides. The anti-inflammatory activity of egg white peptides was examined using a porcine model of dextran sodium sulphate (DSS)-induced colitis. DSS was administered for five days via intra-gastric catheter to induce experimental colitis, followed by five days of treatment with egg white peptides (EWP) or saline. Supplementation with EWP attenuated the DSS-induced clinical symptoms, including weight loss, mucosal and submucosal inflammation, crypt distortion, and colon muscle thickening, and restored gut barrier function by decreasing intestinal permeability and increasing mucin gene expression. Furthermore, treatment with EWP significantly reduced the local expression of pro-inflammatory cytokines TNF-a, IL-6, IL-1b, IFN-c, IL-8, and IL-17, suggesting that EWP is a promising novel therapeutic for the treatment of IBD.
[show abstract][hide abstract] ABSTRACT: Inflammatory bowel disease (IBD) is a chronic and recurring inflammation of the gastrointestinal tract, associated with a dysregulation of the mucosal immune system. There is an increasing prevalence of IBD; however, current pharmaceutical treatments are only moderately effective and have been associated with potential long-term toxicity. Lysozyme, a well-known antimicrobial protein found in large quantities in hen egg white, is a promising alternative for the treatment of IBD. A porcine model of dextran sodium sulfate (DSS)-induced colitis was used to examine the effect of hen egg lysozyme (HEL) supplementation on intestinal inflammation. Treatment with DSS resulted in weight loss, severe mucosal and submucosal inflammation, colonic crypt distortion, muscle wall thickening, down-regulation of mucin gene expression, and increased gastric permeability, but these symptoms were attenuated following supplementation with HEL and restored to basal levels observed in untreated control animals. Treatment with HEL also significantly reduced the local expression of pro-inflammatory cytokines TNF-alpha, IL-6, IFN-gamma, IL-8, and IL-17 while increasing the expression of the anti-inflammatory mediators IL-4 and TGF-beta, indicating that HEL may function as a potent anti-inflammatory and immunomodulator. Furthermore, the concomitant increases in TGF-beta and Foxp3 levels suggest that HEL may aid in restoring gut homeostasis by activating regulatory T cells, which are important in the regulation of the mucosal immune system. These results suggest that HEL is a promising novel therapeutic for the treatment of IBD.
Journal of Agricultural and Food Chemistry 03/2009; 57(6):2233-40. · 2.91 Impact Factor